Alternatively spliced circulating tissue factor

Details Alternatively spliced circulating tissue factor Alternatively spliced circulating tissue factor

2006-05-16

2006-05-16

Carlson, Karen Cochrane (Department: 1653)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S252300, C435S320100, C536S023100, C530S350000, C530S300000, C530S387100

Reexamination Certificate

active

07045350

ABSTRACT:
A new circulating form of soluble human tissue factor was identified. This new form of human tissue factor appears to be the result of alternative splicing and is therefore referred to as “alt-hTF.” Alt-hTF mRNA was detected in a cell line, HL-60. The cDNA region encoding the entire open reading frame of alt-hTF was cloned. The sequence encoding the alt-hTF mature peptide was expressed in bacteria. alt-hTF consists of the first 166 amino acids of membrane bound TF, and a 40 amino acid C-terminal region unique to alt-hTF. Alt-hTF is likely to be a useful target for compounds to inhibit clotting and to treat disorders associated with elevated TF. It may also be useful as a target for antibodies selectively reactive with alt-hTF, to remove it from the circulation for treatment of clotting or other disorders associated with elevated or abnormal levels of TF, including thrombotic conditions, cardiovascular disorders, DVT, DIC, and possibly metastatic cancers.

REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), River et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslaghti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5211947 (1993-05-01), Brannan et al.
patent: 5346991 (1994-09-01), Roy et al.
patent: 5510466 (1996-04-01), Krieger et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5652224 (1997-07-01), Wilson et al.
patent: 5746223 (1998-05-01), Williams
patent: 5925333 (1999-07-01), Krieger et al.
patent: 0 347 262 (1989-12-01), None
patent: 03 290184 (1991-12-01), None
patent: 05 192179 (1993-11-01), None
patent: WO 90/05748 (1990-05-01), None
patent: WO 93/01286 (1993-01-01), None
patent: WO 93/19166 (1993-09-01), None
patent: WO 96/00288 (1996-01-01), None
Chinnalyan et al. 1995; Cell 81:505-512.
*Abdulkadir, et al., “Tissue factor expression and angiogenesis in human prostate carcinoma,” Hum. Pathol. 31: 443-447 (2000).
*Agnelli, et al., Blood 96: 491 (2000) abstract only.
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc Natl Acad Sci 7079-7083(1988).
*Atsumi, et al., “Up-regulated tissue factor expression in antiphospholipid syndrome,” Thromb. Haemost. 77:222-223 (1997).
*Bach, et al., “Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine,” Biochemistry 25(14): 4007-4020 (1986).
*Belch, “The role of the white blood cell in arterial disease,” Blood Coagul. Fibrinolysis 1: 183-192 (1990).
Blume, et al., “Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter,” Nucl. Acids Res. 20:1777-1784 (1992).
Camerer, et al., “Binding of factor VIIa to tissue factor on keratinocytes induces gene expression,” J. Biol. Chem. 275(9): 6580-6585 (2000).
Clackson, et al., “Making antibody fragments using phage display libraries,”Nature352: 624-628 (1991).
*Clauss, et al., “Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration,” J. Exp. Med. 172(6): 1535-1545 (1990).
*Combes, et al., “In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant,” J. Clin. Invest. 104(1): 93-102 (1999).
Cooney, et al., “Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro,” Science 241: 456-459 (1988).
*Corre, et al., “Smoking and leukocyte-counts. Results of an epidemiological survey,” Lancet 2: 632-634 (1971).
Crooke, “Progress toward oligonucleotide therapeutics: pharmacodynamic properties,” FASEB J. 7: 533-539 (1993).
Daugherty, et al., “Polymerase chain reaction the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,” Nucl. Acids Res. 19(9): 2471-2476 (1991).
Donze, et al., “RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase,” Nucl. Acids Res. 30(10): e46 (2002).
Duval-Valentin, et al., “Specific inhibition of transcription by triple helix-forming oligonucleotides,” Proc. Natl. Acad. Sci. USA 89: 504-508 (1992).
*Dvorak, et al., “Fibrin as a component of the tumor stroma: origins and biological significance,” Cancer Metastasis Rev 2: 41-73 (1983).
*Fidler, “Tumor heterogeneity and the biology of cancer invasion and metastasis,” Cancer Res. 38(9): 2651-2660 (1978).
*Folkman, “Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis,” N. Engl. J. Med. 333: 1757-1763 (1995).
*Friedman, et al., “The leukocyte count as a predictor of myocardial infarction,” N. Engl. J. Med. 290(23): 1275-1278 (1974).
*Gando, et al., “Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation,” Thromb. Haemost. 79(6): 1111-1115 (1998).
Giesen, et al., “Blood-borne tissue factor: another view of thrombosis,” Proc. Natl. Acad. Sci. USA 96(5): 2311-2315 (1999).
Gregoriadis, “Liposomes” InDrug Carriers in Biology and Medicine, Chapter 14, Academic Press, pp. 287-341 (1979).
Grigoriev, et al., “A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF KB binding to interleukin-2 receptor a-regulatory sequence,” J. Biol. Chem. 267:3389-3395 (1992)
Guo, et al., “Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells,” Chin. Med. J. 114(1): 30-34 (2001).
Guo, et al., “Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in NB4 cells,” Chin. J. Hematol. 20(9): 453-455 (1999).
*Hathcock, et al., Thromb. Haemost. Supplement, Abstract OC2404 (2001).
Holen, et al., “Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor,” Nucl. Acids Res. 30(8):1757-1766 (2002).
Holt, et al., “An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation,” Mol. Cell. Biol. 8: 963-973 (1988).
*Hu, et al., “Procoagulant activity in cancer cells is dependent on tissue factor expression,” Oncol. Res. 6(7): 321-327 (1994).
Itakura, et al., “Synthesis and use of synthetic oligonucleotides”, inAnn. Rev. Biochem. 53: 323-356 (1984).
Kabat, et al., Sequences of Proteins of Immunological Interest, 4thed. (U.S. Dept. Health and Human Services, Bethesda, MD (1987).
*Key, et al., “Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease,” Blood 91(11): 4216-4223 (1998).
*Kim, et al., “Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease,” Cardiology 93(1-2): 31-36 (2000).
Leadley, et al. “Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents,” J. Pharmacol. Toxicol. Methods 43(2):101-16 (2000).
Leatham, et al., “Increased monocyte tissue factor expression in coronary disease,” Br. Heart J. 73(1): 10-13 (1995).
*Lee, et al., “Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients,” Exp. Mol. M

Affiliated with

Also associated with

Rating

Alternatively spliced circulating tissue factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alternatively spliced circulating tissue factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alternatively spliced circulating tissue factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3642107